Diabetic Retinopathy Research & Clinical Trials

Sponsor - F. Hoffman-La Roche Ltd. (Open to Enrollment)  

Study: CANBERRA BP41321 
A RANDOMIZED, DOUBLE-MASKED, 48-WEEK, PARALLEL-GROUP, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RG7774 IN PATIENTS WITH DIABETES MELLITUS TYPE 1 OR TYPE 2 WITH TREATMENT-NAÏVE DIABETIC RETINOPATHY

Sponsor - F. Hoffmann-La Roche Ltd. (Open to Enrollment) 

Study: PAVILION GR41675 
A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINPATHY (PAVILION)

Previous Diabetic Retinopathy (DR) Studies:

Sub-Investigator, 2016 - 2019
Sponsor: Regeneron
Study: PANORAMA
A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY
https://clinicaltrials.gov/ct2/show/NCT02718326?term=PANORAMA&rank=3

Principal Investigator, 2017 - 2019
Sponsor: Aerpio
Study: TIME-2b

PHASE 2 DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF SUBCUTANEOUSLY ADMINISTERED AKB-9778 15 MG ONCE DAILY OR 15 MG TWICE DAILY FOR 12 MONTHS IN PATIENTS WITH MODERATE TO SEVERE NON-PROLIFERATIVE DIABETIC RETINOPATHY
https://clinicaltrials.gov/ct2/show/NCT03197870?term=TIME-2b&recrs=ab&rank=1

Sub-Investigator, 2007 - 2009
Protocol FVF4296s: An Open-Label Study to Determine the Dynamics of Regression of Neovascularization in Proliferative Diabetic Retinopathy Following Treatment with Intravitreal Ranibizumab.